Floatz logo

Rovalpituzumab Tesirine

Neuroendocrine Prostate Cancer

AbbVieantibody_drug_conjugatePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Neuroendocrine Prostate Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Tarlatamab
Inkeun Park
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Sacituzumab Tirumotecan
Virginia Commonwealth University
Phase 2CCC

View all 35 →

Same molecule, other indications

Rovalpituzumab Tesirine is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
medullary thyroid gland carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
large cell neuroendocrine carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →